MI-63, a novel, non-peptide small-molecule inhibitor, shows promise as an inhibitor of the p53–MDM2 interaction in prostate cancer cells with wild-type p53; however, it has not been tested in paediatric sarcomas (Ding et al, 2006). This evidence concerns the gene TP53 and prostate carcinoma.